Top Markets
Coin of the day
Synairgen plc Synairgen plc

Synairgen plc

SNG
Rankning i aktier #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Aktiekurs
$0.01292666
Senast synkroniserad: 2025-04-08
Marknadsvärde
$157.54K
Förändring (1 dag)
6.84%
Förändring (1 år)
0.00%
Land
GB
Handel Synairgen plc (SNG)

Kategori

P/S-tal för Synairgen plc (SNG)
P/S-tal per August 2026 TTM: 0.00
Enligt Synairgen plc senaste finansiella rapporter och aktiekurs är det aktuella P/S-talet (TTM) 0.00. I slutet av 2022 hade företaget ett P/S-tal på 0.00.
Historik för P/S-tal för Synairgen plc från 2004 till 2026
P/S-tal vid årets slut
År P/S-tal Ändra
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 86.19K 5,474.43%
2017 1.55K 0.00%
2016 0.00 -100.00%
2015 589.54K 12,229.42%
2014 4.78K 0.00%
2013 0.00 0.00%
2012 0.00 -100.00%
2011 68.65 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 134.85 -99.56%
2006 30.85K 158.87%
2005 11.92K 8,695.11%
2004 135.48 0.00%
P/S-tal för liknande företag eller konkurrenter
Företag P/S-tal Skillnad i P/S-tal Land
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE